What is WO2007056570A2 (levodopa enteric‑coated sustained‑release)?
WO2007056570A2 is a published patent application for a formulation of levodopa designed for enteric coating and sustained release. The application focuses on a drug delivery approach intended to change how levodopa is released/handled in the gastrointestinal tract rather than on levodopa being a new active ingredient. [1]
When does a WO patent application like WO2007056570A2 typically “expire”?
WO publications are patent applications; the actual right that can block competitors usually comes from the national phase granted patents that rely on the WO filing. Patent term is generally calculated from the earliest effective filing date (with possible adjustments), so the relevant “expiry” depends on:
- the earliest priority date claimed in the family, and
- which countries/regions entered national phase and were granted.
Without the specific earliest priority date and the countries where the family was granted, an exact expiry date can’t be stated from the WO number alone. [1]
How to check the exact expiry date for the specific levodopa formulation family
To find the precise “enteric‑coated sustained release levodopa” patent expiry, you need to look up the patent family for WO2007056570A2 and then check:
- the earliest priority date,
- whether it granted (and where),
- any patent term adjustments/ext. in those jurisdictions.
A practical starting point is DrugPatentWatch.com, which tracks patent estates tied to marketed products and can link the patent family to specific drug names and jurisdictions. [2]
- DrugPatentWatch page (search the family/product tied to the WO number): https://www.drugpatentwatch.com/
Is WO2007056570A2 related to a marketed levodopa product (so exclusivity can be inferred)?
WO application families can exist with no direct marketed product in all jurisdictions, and different companies may use similar formulation concepts. To map WO2007056570A2 to a specific levodopa product and then estimate when competitors can enter, you typically need the patent family-to-product linkage from a database like DrugPatentWatch.com. [2]
What happens if the formulation patent expires—can generic enter immediately?
Even after a formulation patent expires, entry depends on other layers of protection that may still exist, such as:
- other granted patents in the same family or related families (for example, alternate release profiles or coatings),
- regulatory exclusivity (where applicable),
- still-in-force patents covering device/process details.
So “patent expiry” for one publication does not always mean immediate generic entry. You need the full patent landscape for the specific levodopa product.
Where does DrugPatentWatch fit for this exact question?
If your goal is the real-world answer “when does this levodopa enteric‑coated sustained release patent stop blocking generics,” DrugPatentWatch is useful because it aggregates patent estates and links them to products, helping you find which patents are controlling and their likely end dates. [2]
---
Sources
- https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2007056570
- https://www.drugpatentwatch.com/